Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

By August or September of this year, Petersen said he expects “basically half” of the company’s $8 billion in manufacturing ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

As users continue to leave X (formerly Twitter) en masse, many in favor of the newer Bluesky platform, the European Medicines ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

In the latest twist in its efforts to wrap up years of high-profile opioid litigation, the billionaire family behind the ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

Some six and a half years since its debut, Servier’s U.S. arm has made good on its oncology growth ambitions while managing to stay true to its patient-centric ethos along the way. | Some six and a ...

One of the 30-second spots taps into the intensity of hit shows like “Game of Thrones.” It starts with a medieval royal preparing to go to war in the name of colorectal cancer screening, declaring, ...